‘Death panels’ perilously close to reality

On Friday, the Food and Drug Administration could doom thousands of breast cancer victims. The FDA will be considering the unprecedented step of retroactively revoking approval for Avastin, a drug that represents the last hope for women with late-stage breast cancer. About 17,500 women a year are treated with the drug, which cuts off blood flow to tumors. It does not cure cancer, but it does stop its growth and extend life. Unfortunately, medical miracles don’t come cheap — treating a breast cancer patient with Avastin can cost $90,000 a year.

In 2008, the FDA’s Oncologic Drugs Advisory Committee put Avastin on a track to “accelerated approval” following a clinical study showing 52 percent of the women on the drug showed improvement in “progression-free survival.” On average, Avastin extended the life of patients by 5½ months, but some survive for years. Subsequent clinical studies showed only 36 and 31 percent of women had improved survival rates, a far better outcome than the alternative — death. The FDA confirmed last year that Avastin would be approved pending “improvement in progression-free survival and evidence that survival is not impaired.”

Doctors and patients were then stunned this past summer when the ODAC ruled, by a vote of 12-1, that the drug did not produce clinically meaningful results. Why did the panel deny the obvious evidence of Avastin’s effectiveness? One member of the FDA’s panel, Jean Grem of the University of Nebraska, said, “We aren’t supposed to talk about cost, but that’s another issue.” If the FDA follows through on the ODAC’s finding and revokes Avastin’s approval, both the government and private insurers will quickly cease paying for its use on breast cancer sufferers.

The Obama administration wants to ration health care in order to help pay for universal coverage and other Obamacare goodies. Donald Berwick, President Barack Obama’s controversial nominee to head the Centers for Medicare and Medicaid Services, has explicitly endorsed rationing. The CMS is now considering whether to refuse Medicare payments for Provenge — another expensive but effective late-stage prostate cancer treatment.

Government bean counters were never supposed to determine what your treatment options are, and patient advocacy groups are justifiably outraged. If Avastin and other expensive wonder drugs are denied approval because of costs, proponents of government-run health care will have to no choice but to admit “death panels” have gone from rhetoric to reality.

AvastineditorialsOpinionSan Francisco

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Parents and students line up socially distanced before the first day of in-person learning at Bret Harte Elementary School on Monday, April 12, 2021. (Kevin N. Hume/S.F. Examiner)
‘It’s a beautiful sight’: The first students return to the classroom

San Francisco’s youngest public school students stepped into classrooms for in-person learning… Continue reading

File
Latest Breed nominee for Police Commission moves forward

Immigration attorney Jim Byrne clears Board of Supervisors committee

A rally at Golden Gate Park on Sunday April 11 drew a large crowd in support of calls to keep JFK Drive closed to traffic. (Emily Huston/Special to the S.F. Examiner)
Hundreds rally for “JFK Thrive,” not JFK Drive

By Emily Huston More than two hundred gathered on a warm Sunday… Continue reading

San Francisco Giants pitcher Anthony DeSclafani (26) starts against the Colorado Rockies at Oracle Park on April 11, 2021 in San Francisco, California. (Photography by Chris Victorio | Special to the S.F. Examiner).
Giants finish sweep of Rockies behind DeSclafani’s scoreless outing

Even with fans back at Oracle Park, San Francisco Giants pitchers have… Continue reading

Kindergarten teacher Chris Johnson in his classroom at Bryant Elementary School ahead of the school’s reopening on Friday, April 9, 2021. (Kevin N. Hume/S.F. Examiner)
SFUSD students are going back to the classroom

After more than a year of distance learning, city schools begin reopening on Monday

Most Read